Evidence map›Paper›PMID 33707434›Full record

ArticleNature communications2021

mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation.

Yilei Zhang, Robert V Swanda, Litong Nie, Xiaoguang Liu, Chao Wang, Hyemin Lee, Guang Lei, Chao Mao, Pranavi Koppula, Weijie Cheng and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 418 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
418citing papers in PubMed, 1 pooled it
43.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

418 citing papers in PubMed, 1 synthesis or guideline pooled it, 678 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

358 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yilei ZhangDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert V SwandaGraduate Field of Biomedical and Biological Sciences, Cornell University, Ithaca, NY, USA.
Litong NieDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0326-4517
Xiaoguang LiuDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6977-5128
Chao WangDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hyemin LeeDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guang LeiDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3282-0666
Chao MaoDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pranavi KoppulaDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7567-1891
Weijie ChengDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jie ZhangDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhenna XiaoDepartment of Genetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhuangDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bingliang FangDepartment of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Junjie ChenDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1493-2189
Shu-Bing QianGraduate Field of Biomedical and Biological Sciences, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-4127-1136
Boyi GanDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. bgan@mdanderson.org.ORCID 0000-0001-8884-6040
The University of Texas MD Anderson Cancer Center · USCornell University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
University of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MERIC-BERNSTAM, FUNDA, ROTH, JACK · 2017 to 2022
$7.7M
CHEMISTRY OF BIOLOGICAL SYSTEMST32GM008500 · NIGMS · CORNELL UNIVERSITY ITHACA · PI LIN, HENING · 1996 to 2020
$5.4M
Studying metabolic stress signaling in renal cancerR01CA181196 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2014 to 2024
$3.4M
Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translationR01CA244144 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2020 to 2024
$2.1M
Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translationR01CA247992 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2021 to 2025
$1.9M
Dynamic mRNA m6A modification in oncogenic translationR21CA227917 · NCI · CORNELL UNIVERSITY · PI QIAN, SHU-BING · 2018 to 2019
$371k
Howard Hughes Medical Institute 55108556NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA181196NCI NIH HHS R01 CA244144NCI NIH HHS R01 CA247992NCI NIH HHS R21 CA227917NCI NIH HHS U54 CA224065NIGMS NIH HHS T32 GM008500
6 · The paper itself

Abstract

Glutathione peroxidase 4 (GPX4) utilizes glutathione (GSH) to detoxify lipid peroxidation and plays an essential role in inhibiting ferroptosis. As a selenoprotein, GPX4 protein synthesis is highly inefficient and energetically costly. How cells coordinate GPX4 synthesis with nutrient availability remains unclear. In this study, we perform integrated proteomic and functional analyses to reveal that SLC7A11-mediated cystine uptake promotes not only GSH synthesis, but also GPX4 protein synthesis. Mechanistically, we find that cyst(e)ine activates mechanistic/mammalian target of rapamycin complex 1 (mTORC1) and promotes GPX4 protein synthesis at least partly through the Rag-mTORC1-4EBP signaling axis. We show that pharmacologic inhibition of mTORC1 decreases GPX4 protein levels, sensitizes cancer cells to ferroptosis, and synergizes with ferroptosis inducers to suppress patient-derived xenograft tumor growth in vivo. Together, our results reveal a regulatory mechanism to coordinate GPX4 protein synthesis with cyst(e)ine availability and suggest using combinatorial therapy of mTORC1 inhibitors and ferroptosis inducers in cancer treatment.

Indexed as

Amino Acid Transport System y+Cell Line, TumorCysteineCystineFerroptosisGene Knockout TechniquesGlutathioneHEK293 CellsHumansMechanistic Target of Rapamycin Complex 1NeoplasmsPhospholipid Hydroperoxide Glutathione PeroxidaseAmino Acid Transport System y+CysteineCystineGlutathioneMechanistic Target of Rapamycin Complex 1Phospholipid Hydroperoxide Glutathione PeroxidaseSLC7A11 protein, human

Identifiers

PMID33707434
PMCPMC7952727
OpenAlexW3133823534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.